On December 9, 2025, Moleculin Biotech, Inc. announced that 78% of the target subjects for its Phase 2B/3 MIRACLE study for treating acute myeloid leukemia have been enrolled, up from 60%, with 45 subjects targeted for the first data unblinding expected in early 2026.